Thromboembolic Events in Patients With Colorectal Cancer Receiving the Combination of Bevacizumab-Based Chemotherapy and Erythropoietin Stimulating Agents

Abstract

The incidence of thromboembolic events was increased with the combination of bevacizumab plus ESA compared with either agent alone with chemotherapy. Median time-to-event in the combination group was significantly shorter compared with the bevacizumab group. Prior VTE, cardiac disease, obesity, and exogenous hormone use should be taken in consideration when using the combination of bevacizumab and ESAs.